Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standardized grass pollen + grass mix 4 is a standardized allergenic extract biologic used for the diagnosis and immunotherapy of grass pollen allergy, including hay fever and allergic rhinitis in sensitized patients. The product contains a defined mixture of grass pollens from *Agrostis gigantea*, *Dactylis glomerata*, *Phleum pratense*, and *Poa pratensis*, and is manufactured by Jubilant HollisterStier. Administered as an injectable solution via percutaneous and subcutaneous routes, it functions through allergen-specific immunotherapy or hyposensitization, repeatedly exposing the immune system to relevant grass pollen allergens to reduce subsequent allergic responsiveness. The extract is standardized against FDA reference preparations and labeled in Bioequivalent Allergy Units per milliliter, with marketed potencies including 10000 BAU/mL and 100000 BAU/mL.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standardized grass pollen + grass mix 4.